Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bromocriptine mesylate
Drug ID BADD_D00305
Description Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It is indicated for the management of signs and symptoms of Parkinsonian Syndrome. Bromocriptine also inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. It also causes sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly. Bromocriptine has been associated with pulmonary fibrosis.
Indications and Usage For the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodopa in advanced cases with motor complications. Bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome.
Marketing Status Prescription; Discontinued
ATC Code G02CB01; N04BC01
DrugBank ID DB01200
KEGG ID D00780
MeSH ID D001971
PubChem ID 31100
TTD Drug ID D06YFA
NDC Product Code 65841-654; 60687-286; 0781-5325; 55486-1561; 51927-2274; 30698-202; 30698-201; 0378-7096; 68012-258; 0574-0106; 68382-110
Synonyms Bromocriptine | 2-Bromo-alpha-ergokryptine | 2 Bromo alpha ergokryptine | Bromocryptin | 2-Bromoergokryptine | 2 Bromoergokryptine | Bromocriptin | 2-Bromoergocryptine | 2 Bromoergocryptine | 2-Bromo-alpha-ergocryptine | 2 Bromo alpha ergocryptine | CB-154 | CB 154 | CB154 | Parlodel | 2-Bromoergocryptine Mesylate | 2 Bromoergocryptine Mesylate | Mesylate, 2-Bromoergocryptine | Bromocriptine Mesylate | Mesylate, Bromocriptine | 2-Bromoergocryptine Methanesulfonate | 2 Bromoergocryptine Methanesulfonate | Methanesulfonate, 2-Bromoergocryptine
Chemical Information
Molecular Formula C33H44BrN5O8S
CAS Registry Number 22260-51-1
SMILES CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CN(C5CC6=C(NC7=CC=CC(=C67)C5=C 4)Br)C)O.CS(=O)(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Acromegaly15.03.01.018; 14.11.01.029; 05.03.01.005; 24.08.04.004--Not Available
Agitation19.06.02.001; 17.02.05.012--
Alcohol intolerance14.02.01.001--
Alopecia23.02.02.001--
Amblyopia06.02.01.001--Not Available
Anxiety19.06.02.002--
Arrhythmia02.03.02.001--Not Available
Asthenia08.01.01.001--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Binge eating19.09.01.001--Not Available
Blepharospasm17.17.02.001; 06.05.01.001--Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.002--Not Available
Burning sensation17.02.06.001; 08.01.09.029--Not Available
Cardiac failure congestive02.05.01.002--Not Available
Cerebrospinal fluid leakage17.02.05.001; 12.01.10.004--
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Confusional state17.02.03.005; 19.13.01.001--
Constipation07.02.02.001--
Delirium19.13.02.001--
Delusion19.10.01.001--
Delusional perception19.10.02.006--Not Available
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Diabetes mellitus05.06.01.001; 14.06.01.001--Not Available
Diarrhoea07.02.01.001--
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages